Characteristics of responders to atropine 0.01% as treatment in Asian myopic children

Sci Rep. 2022 May 5;12(1):7380. doi: 10.1038/s41598-022-10978-3.

Abstract

Recently, low-concentration atropine (0.01%) has gained increased attention in controlling myopia progression with satisfying effects and minimal side effects. However, studies concerning responders to 0.01% atropine are limited. This retrospective observational cohort study aimed to determine the responder characteristics of 0.01% atropine in Asian children. One hundred forty children (aged between 3 and 15 years) receiving 0.01% atropine were analyzed for the factors influencing annual spherical equivalent changes (SE). The mean age was 9.13 (2.6) years, the mean baseline SE was - 1.56 (1.52) diopters (D), and the mean annual SE change was - 0.52 (0.49) D. A 58.63% responder rate (146/249) of myopic control was achieved with 0.01% atropine in our entire cohort under the criteria of less than 0.5 D of myopic progression annually. The subjects were stratified into 4 subgroups based on a cut-off point of baseline SE of - 1.5 D and baseline age of 9 years. The responder rate differed significantly with the highest being the youngest with the lowest myopia subgroups. Our results demonstrated that children with myopia better than - 1.5 D and younger than 9 years had the highest potential to achieve successful myopic control under 0.01% atropine therapy.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Atropine*
  • Child
  • Child, Preschool
  • Disease Progression
  • Humans
  • Mydriatics
  • Myopia* / drug therapy
  • Ophthalmic Solutions / therapeutic use
  • Refraction, Ocular
  • Retrospective Studies

Substances

  • Mydriatics
  • Ophthalmic Solutions
  • Atropine